FDA Approved New Liquid Formulation of Lamotrigine
The oral suspension offers a new option for children and adults who struggle with solid medication dosages.
Updated on Sept. 28, 2026 in Substance Abuse
Live Poll
Do you trust that new liquid medication formats significantly improve the treatment experience for patients?
The FDA has approved Lamlique, a new liquid formulation of lamotrigine designed for patients aged 2 years and older. This ready-to-use oral suspension provides an alternative administration method for individuals managing epilepsy or bipolar I disorder.
Why it matters
For the approximately 3.4 million people in the United States living with epilepsy, this approval addresses the need for greater dosing flexibility. It provides a non-solid alternative that eliminates the requirement for compounding or refrigeration.
The FDA approved Lamlique for use in patients aged 2 years and older as an adjunctive therapy for specific seizure types or maintenance for bipolar I disorder. The clinical evidence supports the drug's role in providing a liquid alternative for a population of 3.4 million.
The players
FDA
The federal agency responsible for protecting public health by ensuring the safety and efficacy of human and veterinary drugs.
The details
Lamlique functions as an adjunctive therapy for partial-onset seizures, primary generalized tonic-clonic seizures, and Lennox-Gastaut syndrome. For patients with bipolar I disorder, the drug acts to extend the interval between mood episodes. The suspension is formulated in two strengths, 5 mg/mL and 25 mg/mL, to assist those who require alternatives to tablets.
Timeline
September 28, 2026: The FDA officially approved Lamlique oral suspension.
End of 2026: The medication is expected to be available for patient use.
Health Landscape
This development follows the established regulatory pattern of approving new formulations for existing medications to improve patient adherence. It expands the therapeutic landscape for epilepsy care by providing a versatile, ready-to-use liquid option for a broad patient population.
If you or a family member struggle with swallowing solid medications, this liquid formulation may offer a more manageable daily routine. Discuss with your physician whether this new administration method could be an appropriate addition to your current epilepsy or bipolar treatment plan.
The takeaway
This new liquid option simplifies medication administration for those who require dosing flexibility in managing seizures or bipolar I disorder. Always consult your doctor to determine if a transition to this suspension is appropriate for your specific treatment regimen.
Further reading
For more on evolving treatment options and management strategies, visit Substance Abuse.
Live Poll
Do you trust that new liquid medication formats significantly improve the treatment experience for patients?
